Stronger anticancer effect in animals with KRAS and BRAF mutant by decreasing intracellular glucose and energy production due to intracellular ROS accumulation and GAPDH inhibition compared wild type tumor (P < 0.05). The gene discussed is KRAS; the disease is neoplasm.